These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31012492)

  • 21. Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.
    Ward J; Graham N; Strawbridge RJ; Ferguson A; Jenkins G; Chen W; Hodgson K; Frye M; Weinshilboum R; Uher R; Lewis CM; Biernacka J; Smith DJ
    PLoS One; 2018; 13(9):e0203896. PubMed ID: 30240446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1.
    Nunez JJ; Nguyen TT; Zhou Y; Cao B; Ng RT; Chen J; Frey BN; Milev R; Müller DJ; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
    PLoS One; 2021; 16(6):e0253023. PubMed ID: 34181661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.
    Cutler JA; Rush AJ; McMahon FJ; Laje G
    J Psychopharmacol; 2012 Mar; 26(3):360-7. PubMed ID: 22282879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.
    Phaterpekar T; Nunez JJ; Morton E; Liu YS; Cao B; Frey BN; Milev RV; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW
    J Clin Psychiatry; 2023 Nov; 85(1):. PubMed ID: 37967350
    [No Abstract]   [Full Text] [Related]  

  • 25. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
    Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
    J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.
    Su YA; Bousman CA; Liu Q; Lv XZ; Li JT; Lin JY; Yu X; Tian L; Si TM
    Pharmacogenet Genomics; 2021 Oct; 31(8):172-176. PubMed ID: 34081644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
    Amare AT; Schubert KO; Tekola-Ayele F; Hsu YH; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Kato M; Liu YL; Praphanphoj V; Stingl JC; Bobo WV; Tsai SJ; Kubo M; Klein TE; Weinshilboum RM; Biernacka JM; Baune BT
    Front Psychiatry; 2018; 9():65. PubMed ID: 29559929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
    Davis LL; Wisniewski SR; Howland RH; Trivedi MH; Husain MM; Fava M; McGrath PJ; Balasubramani GK; Warden D; Rush AJ
    Drug Alcohol Depend; 2010 Mar; 107(2-3):161-70. PubMed ID: 19945804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.
    Guilloux JP; Bassi S; Ding Y; Walsh C; Turecki G; Tseng G; Cyranowski JM; Sibille E
    Neuropsychopharmacology; 2015 Feb; 40(3):701-10. PubMed ID: 25176167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.
    ; ;
    Am J Psychiatry; 2013 Feb; 170(2):207-17. PubMed ID: 23377640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.
    Srivastava A; Singh P; Gupta H; Kaur H; Kanojia N; Guin D; Sood M; Chadda RK; Yadav J; Vohora D; Saso L; Kukreti R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
    Peters EJ; Slager SL; Kraft JB; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
    PLoS One; 2008 Apr; 3(4):e1872. PubMed ID: 18382661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
    Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
    Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
    Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study.
    Ishak WW; Christensen S; Sayer G; Ha K; Li N; Miller J; Nguyen JM; Cohen RM
    J Clin Psychiatry; 2013 Mar; 74(3):256-61. PubMed ID: 23561231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.
    Tammiste A; Jiang T; Fischer K; Mägi R; Krjutškov K; Pettai K; Esko T; Li Y; Tansey KE; Carroll LS; Uher R; McGuffin P; Võsa U; Tšernikova N; Saria A; Ng PC; Eller T; Vasar V; Nutt DJ; Maron E; Wang J; Metspalu A
    J Psychopharmacol; 2013 Oct; 27(10):915-20. PubMed ID: 23926243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.